Vantus Wealth’s AbbVie ABBV Stock Holding History

Vantus Wealth’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.25M	Buy	+4,974	New	+$1.07M	0.67%	31
2025 Q4	$869K	Buy	+3,803	New	+$866K	0.64%	39

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vantus Wealth's ABBV Position: Q2 2026 in Review

Vantus Wealth opened a new position in AbbVie (ABBV) in Q2 2026: 4,974 shares worth $1.25M. The stake represents 0.67% of the portfolio and ranks #31 among its holdings. This is a return to the name: Vantus Wealth previously reported a position in ABBV as recently as Q4 2025.

Vantus Wealth first reported a position in ABBV in Q4 2025 and has held it in 2 quarters since. 4,207 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Vantus Wealth held 4,974 shares of AbbVie worth $1.25M as of Q2 2026.
AbbVie was a new Vantus Wealth position in Q2 2026.
AbbVie made up 0.67% of Vantus Wealth's portfolio in Q2 2026, its #31 holding.
Vantus Wealth first reported a position in AbbVie in Q4 2025 and has held it in 2 quarters since.
4,207 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Vantus Wealth's 13F filing for Q2 2026, filed 7 Aug 2026.